Recent Antibiotics Celebrated as a 'Major Shift' in Combating Antibiotic-Resistant Gonorrhoea
The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the infection, according to researchers.
A Worldwide Challenge
Cases of gonorrhoea are increasing around the world, with figures suggesting in excess of 82 million new cases per year. Notably increased rates are reported in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.
“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs at this time.”
Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.
Recent Therapies Receive Clearance
One new antibiotic, marketed under the name a brand name, was approved by the US FDA in recent days for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts hope that targeted use of this new drug will help delay the spread of drug resistance.
Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is employed against urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.
A Unique Partnership
This new treatment emerged from a new, not-for-profit approach for drug creation. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to bring it to fruition.
“This milestone marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”
Testing Outcomes and Worldwide Availability
Based on data published in a major medical journal, zoliflodacin successfully treated more than 90% of uncomplicated infections. This puts it on an equal footing with the existing first-line therapy, which uses two antibiotics. The study involved over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.
As part of the agreement of its development partnership, GARDP has the authority to register and commercialise the drug in many regions with limited resources.
Doctors on the front lines have shared optimism. Access to a easy-to-administer therapy of this kind is seen as a "game-changer" for gonorrhoea control. This is viewed as vital to alleviate the strain of the infection for individuals and to prevent the spread of untreatable gonorrhoea around the world.
